May Hill Capital’s MaxCyte MXCT Stock Holding History

May Hill Capital’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-12,382	Closed	-$27K	–	204
2025 Q2	$27K	Buy	+12,382	New	+$30K	0.01%	205

Other funds holding MXCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

MFS

Mirabella Financial Services London, United Kingdom $1.05B AUM 22.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return

AIM

AXA Investment Managers Puteaux, France $37.1B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

May Hill Capital's MXCT Position: Q3 2025 in Review

May Hill Capital sold out of MaxCyte (MXCT) in Q3 2025, closing a stake of 12,382 shares — an estimated $27K sold.

May Hill Capital first reported a position in MXCT in Q2 2025 and held it in 1 quarter. The position peaked at $27K in Q2 2025. 112 funds tracked by Wall St. Rank hold MXCT as of Q3 2025.

May Hill Capital reported no remaining MaxCyte position as of Q3 2025 after selling out during the quarter.
May Hill Capital sold 12,382 MaxCyte shares in Q3 2025, an estimated $27K.
May Hill Capital first reported a position in MaxCyte in Q2 2025 and held it in 1 quarter.
May Hill Capital's MaxCyte position peaked at $27K in Q2 2025.
112 funds tracked by Wall St. Rank held MaxCyte as of Q3 2025.

Based on May Hill Capital's 13F filing for Q3 2025, filed 7 Nov 2025.